Skip to main content
. 2018 Oct 25;11:1756286418805713. doi: 10.1177/1756286418805713

Figure 4.

Figure 4.

NEDA-3+CLs. Left panel: Percentage of patients treated with natalizumab (black bars) or fingolimod (grey bars) that achieved NEDA-3 + CL status at each timespan (T0–T1, T1–T2, T0–T2). *p < 0.05; ***p < 0.005. Right panel: Survival curves showing the proportion of patients that achieved the NEDA-3 + CL status (natalizumab: black line, fingolimod: grey line).

CL, cortical lesion; NEDA, no evidence of disease activity.